News
![astellas_sign](https://pharmaphorum.com/wp-content/uploads/2022/10/astellas_sign.jpg)
Astellas nabs lead in claudin 18.2 after positive stomach ca...
Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or gastroesopha